Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pmgc Holdings Q3 2026 Results: Net Loss of $2.41M, Loss Narrows

PMGC Holdings Inc. reported a significant revenue increase to $4.52 million for the nine months ended September 30, 2026, compared to $0.29 million in the prior year. However, net loss widened to $10.15 million due to increased operating expenses and interest costs, while the company underwent a series of reverse stock splits totaling 1-for-240.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.50.3
Gross profit0.60.1
Net income-2.4-2.6

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+784.9%
Gross margin23.8%
Source

10-Q filed with the SEC, NASDAQ: ELAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pmgc Holdings Inc.: key numbers

Share price
$1.66Close, Nov 16
Market cap
$1.94M
Shares outstanding
1.17MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pmgc Holdings Inc.

All →
4:01 PM ET 8-K
Clinical Trial Data

Pmgc Holdings Clinical Trial Data

PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.

4:01 PM ET 8-K
Equity Investment

Pmgc Holdings Equity Investment of $1.84M in Nuclea Energy Canada Inc.

PMGC Holdings Inc. entered into a subscription agreement to invest $1.845 million in secured debentures of Nuclea Energy Canada Inc. The investment is part of a larger $9 million offering intended to fund Nuclea Canada's acquisition of assets from Moltex Energy Limited. The debentures are non-interest bearing, non-convertible, and mature in three months or upon certain corporate events.

Value
$1.84M
Counterparty
Nuclea Energy Canada Inc.
Term
3 months
4:01 PM ET 8-K
Investor Presentation

Pmgc Holdings Investor Presentation

PMGC Holdings Inc. (doing business as NorthStrive Holdings Inc.) filed a formal investor presentation slide deck and a specific deck related to its Maritime Defense Technology. The materials are intended for use in upcoming presentations to investors and analysts regarding the company's strategy and operations.

8:02 AM ET 8-K
Other 8-K Filing

Pmgc Holdings Other 8-K Filing

PMGC Holdings and its subsidiary NorthStrive Biosciences entered into a binding payment agreement with Longevity Health Holdings to secure royalty payments from the 2025 sale of the Elevai Skincare business. The agreement converts a 5% net sales royalty into scheduled monthly cash payments through August 2031, including interest and mandatory prepayments tied to future capital events. This restructuring provides PMGC with visible, non-dilutive cash flow while allowing it to focus on its core manufacturing and defense technology segments.

Counterparty
Longevity Health Holdings, Inc.
Term
through Aug 2031

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.